Neurocrine Biosciences, Inc. (NBIX) Expected to Announce Earnings of $0.12 Per Share
Brokerages expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report earnings of $0.12 per share for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Neurocrine Biosciences’ earnings, with estimates ranging from $0.01 to $0.23. Neurocrine Biosciences reported earnings per share of $0.07 during the same quarter last year, which would indicate a positive year over year growth rate of 71.4%. The firm is expected to issue its next earnings results on Tuesday, February 12th.
On average, analysts expect that Neurocrine Biosciences will report full year earnings of $0.19 per share for the current fiscal year, with EPS estimates ranging from $0.05 to $0.43. For the next fiscal year, analysts anticipate that the business will report earnings of $1.74 per share, with EPS estimates ranging from $0.73 to $2.78. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Neurocrine Biosciences.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Monday, November 5th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.04. The company had revenue of $151.80 million for the quarter, compared to analysts’ expectations of $151.51 million. Neurocrine Biosciences had a return on equity of 2.54% and a net margin of 2.40%. The firm’s quarterly revenue was up 149.7% compared to the same quarter last year. During the same period last year, the business posted ($0.13) earnings per share.
In related news, Director Richard F. Pops sold 5,500 shares of Neurocrine Biosciences stock in a transaction dated Monday, October 29th. The stock was sold at an average price of $107.13, for a total transaction of $589,215.00. Following the transaction, the director now directly owns 37,759 shares of the company’s stock, valued at $4,045,121.67. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Richard F. Pops sold 4,123 shares of Neurocrine Biosciences stock in a transaction dated Monday, November 12th. The stock was sold at an average price of $103.30, for a total value of $425,905.90. Following the transaction, the director now directly owns 33,636 shares in the company, valued at $3,474,598.80. The disclosure for this sale can be found here. Insiders have sold 33,623 shares of company stock worth $3,721,361 over the last three months. Corporate insiders own 4.30% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. increased its stake in Neurocrine Biosciences by 643.7% in the 2nd quarter. Meeder Asset Management Inc. now owns 1,123 shares of the company’s stock worth $110,000 after purchasing an additional 972 shares in the last quarter. Steward Partners Investment Advisory LLC acquired a new stake in Neurocrine Biosciences during the 3rd quarter worth about $127,000. TRUE Private Wealth Advisors acquired a new stake in Neurocrine Biosciences during the 3rd quarter worth about $127,000. Signaturefd LLC boosted its position in Neurocrine Biosciences by 295.9% during the 3rd quarter. Signaturefd LLC now owns 1,338 shares of the company’s stock worth $165,000 after acquiring an additional 1,000 shares during the period. Finally, Financial Architects Inc boosted its position in Neurocrine Biosciences by 283.7% during the 3rd quarter. Financial Architects Inc now owns 1,385 shares of the company’s stock worth $170,000 after acquiring an additional 1,024 shares during the period. 98.88% of the stock is currently owned by hedge funds and other institutional investors.
NBIX stock opened at $89.98 on Friday. The firm has a market capitalization of $8.16 billion, a price-to-earnings ratio of -55.54, a P/E/G ratio of 23.02 and a beta of 0.94. Neurocrine Biosciences has a 1 year low of $67.32 and a 1 year high of $126.98.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.
See Also: Bond
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.